ATM-Altered Prostate Cancer May Be Especially Sensitive to Lu-177-PSMA
A new study suggests that ATM alterations could identify a subgroup of metastatic castration-resistant prostate cancer particularly likely to benefit from 177Lu-PSMA-617 (Pluvicto). The retrospective analysis included 205 men with mCRPC treated with Lu-177-PSMA-617 between 2022 and 2026, all of whom had next-generation DNA sequencing available. ATM alterations were present in 12.7% of patients and […]
